Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Aggression · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Global outcome ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ movement disorders · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether RISPERIDONE changes adverse effects: movement disorders, over 24 hours compared with COMBINATION: b. RISPERIDONE + VALPROIC ACID (very low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether RISPERIDONE changes specific behaviour: agitation, up to 24 hours (PANSS‐PAS response) compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: need for additional measures · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether RISPERIDONE changes global outcome: need for additional measures compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects: up to 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether RISPERIDONE changes adverse effects: up to 24 hours compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep by 30 minutes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Mental state: significant response or improvement in negative symptoms (PANSS negative subscale, high = worse) ‐ short term (12 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes mental state: significant response or improvement in negative… compared with placebo (very low certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · adults with schizophrenia
1 finding from 1 review
Clinical global response: significant response or improvement in global status (CGI‐S, high = worse) ‐ short term (4 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes clinical global response: significant response or improvement in… compared with placebo (very low certainty).
1 finding from 1 review
Cognitive functioning: significant response or improvement in cognitive functioning · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive function: average endpoint score** · adults with schizophrenia
1 finding from 1 review
QoL · adults with schizophrenia
1 finding from 1 review
Nausea · adults with schizophrenia
Noradrenaline reuptake inhibitors showed no clear difference in adverse effects: Nausea ‐ short term (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · people with both severe mental illness and substance misuse
1 finding from 1 review